Sofinnova Partners closed a second crossover fund with €725 million to back late-stage European biotechs and medtech companies, aiming to address a persistent financing gap for companies approaching commercialization. The firm said the pool will support a new group of later-stage programs across Europe, building on Sofinnova’s history of backing companies such as Abivax, Argenx, and Verona Pharma. For biotech investors, the new fund highlights continued demand for bridge capital between venture rounds and large-cap public-market liquidity—particularly in oncology and specialty therapeutics.
Get the Daily Brief